

Cont  
a2  
intraperitoneally with PAK wildtype at 3LD<sub>50</sub>. Mice were monitored on a hourly basis between 16 and 48 hours. As seen in Figure 9, percent survival was dose dependent within the range of pilin protein amounts tested.

Sev  
a3  
After page 15, please add pages 1-9 of the sequence listing attached hereto as Exhibit A.

**IN THE CLAIMS**

Please add Claim 20 as follows:

a4  
Claim 20 (newly added) A method of treating or preventing infection by *Pseudomonas aeruginosa* comprising administering a pharmaceutically acceptable amount of an isolated pilin peptide having the amino acid sequence set forth in SEQ ID Nos. 4, 6, 8, or 10.

Please ~~cancel~~ Claims 1-19 without prejudice or disclaimer.

**REMARKS**

Applicants respectfully request that the Preliminary Amendment be entered prior to the examination of the above-identified application.

Applicants submit that the Preliminary Amendment makes changes to the Specification for priority purposes and in accordance with those changes made to U.S. Patent Application No. 09/329,884. Claim 20 has been newly added for reconsideration upon examination.

Accordingly, Applicants respectfully request early and favorable consideration of the present application.

Respectfully submitted,



Robert M. Barrett (Reg. No. 30,142)  
BELL, BOYD & LLOYD LLC  
P.O. Box 1135  
Chicago, Illinois 60690-1135  
(312) 807-4204  
ATTORNEY FOR APPLICANTS